Despite these limitations, there has been considerable agreement among the published studies in transgenic (e.g., PD-1-deficient) mice, immunotherapeutic studies in murine infection models, assessment of ex-vivo human and murine immune cells, and clinical case reports regarding the effects of checkpoint induction and inhibition in a broad spectrum of IFIs. The gene discussed is PDCD1; the disease is infection.